Paper
0
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
Authors
Luisa Villa,Gonzalo Pérez
Susanne Kjær,Jorma Paavonen,Matti Lehtinen,Nubia Muñóz,Kristján Sigurðsson,Mauricio Hernández‐Ávila,Finn Skjeldestad,Steinar Thoresen,Patricia García,Sławomir Majewski,Joakim Dillner,Sven-Eric Olsson,Heather Eng,F. Bosch,Kevin Ault,Darron Brown,Daron Ferris,Laura Koutsky,Robert Kurman,Evan Myers,Eliav Barr,John Boslego,Janine Bryan,Mark Esser,Christine Gause,Teresa Hesley,Lisa Lupinacci,Heather Sings,Frank Taddeo,A. Thornton,Sven Olsson,Hseon Eng
+32 authors
,Annemarie ThorntonPublished
May 9, 2007
Show more
Save
Tip0
TipSave
Abstract
Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.